Investigational drug · Phase 3
SHR-A1921
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Ovarian Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: May 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
17
Any phase or sponsor naming "SHR-A1921"
First trial start
2024
May 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-A1921", any sponsor or status.
- Phase 214
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Ovarian Cancer
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-A1921" as an intervention, largest first.
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- SNF Platform Study of HR+/ HER2-advanced Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05594095 · 620 participants (planned) · Start Dec 30, 2022 · Primary completion Dec 1, 2025
Drug: PIK3CA inhibitor; AKT inhibitor and 17 more · For: Breast Neoplasm; Breast Cancer; Hormone Receptor Positive Tumor and 2 more
Sites: Shanghai, China
- A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian CancerPivotal-lookingStatus unknown
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06211023 · 520 participants (planned) · Start Feb 15, 2024 · Primary completion Jun 15, 2026
Drug: SHR-1921; carboplatin and 2 more · For: Ovarian Cancer
- SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerPivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06394492 · 440 participants (planned) · Start May 10, 2024 · Primary completion May 31, 2026
Drug: SHR-A1921; Doxorubicin and 2 more · For: Ovarian Cancer
Sites: Beijing, China; Hangzhou, China
- Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid TumorsStatus unknown
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT05765032 · 220 participants · Start Dec 30, 2022 · Primary completion Apr 30, 2025
Drug: SHR-A1921; · For: Advanced Solid Tumor
Sites: Tianjin, China
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT06649331 · 160 participants (planned) · Start Oct 21, 2024 · Primary completion Sep 2026
Drug: SHR-A1811; SHR-A1921 and 7 more · For: Advanced Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer (TNBC) and 2 more
Sites: Shanghai, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT05154604 · 156 participants (planned) · Start Dec 31, 2021 · Primary completion Aug 31, 2024
Drug: SHR-A1921 · For: Advanced Solid Tumours
- A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsPivotal-lookingRecruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06474455 · 156 participants (planned) · Start Jul 2, 2024 · Primary completion Jun 2029
Drug: SHR-9839 for Injection; SHR-A1921 for Injection and 7 more · For: Advanced Solid Tumors
Sites: Zhengzhou, China; Hangzhou, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06520488 · 118 participants (planned) · Start Aug 9, 2024 · Primary completion Mar 2027
Drug: HRS-4642 · For: Advanced Solid Tumors
Sites: Shanghai, China
Beijing GoBroad HospitalAcademic, hospital or other
NCT06433609 · 113 participants (planned) · Start Aug 5, 2024 · Primary completion Mar 2027
Drug: SHR-A1811; SHR-A1921 and 2 more · For: Advanced Breast Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma.
Chen GL, Guo Y, Yang Y, et al. · NPJ Precis Oncol 2026
- Preclinical activity of SHR-A1921, a novel antibody-drug conjugate targeting trophoblast cell-surface antigen2 (Trop-2) in prostate cancer.
Wang B, Xu Q, Peng S, et al. · Front Pharmacol 2026
- Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer.
Patel SP, Gadgeel S, Mino-Kenudson M, et al. · Cancer Treat Rev 2026
- TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.
Zhong J, Wu L, Song Z, et al. · Cancer Cell 2025
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.